Bio Spectrum August 2017

(^14) COMPANY NEWS l BioSpectrum | August 2017 | http://www.biospectrumindia.com
Piramal Enterprises is looking to
expand presence of its pharma
vertical in global markets such as
the US, Europe and Japan with
plans to introduce more products
going forward. North America
and Europe account for over 70
per cent of the company’s revenue
from pharmaceuticals business.
Piramal’s pharma vertical
is divided into two- the global
pharma
business that sells pharma
products and services globally
and the India consumer products
business that sells OTC products
in India.
The company operates through
its own field force in the US,
the UK, Italy, and Germany and
through more than 80 business
partners in other countries. It has
distribution presence in over 110
countries across the world.
It has four plants in North
America and two plants in the UK
and has dedicated sales force in
North America and Europe. In
the US it has 30 per cent market
share in inhalation anaesthesia.
In the current fiscal, the company
plans to launch Desflurane, the
latest generation of inhalation
anaesthesia.
Piramal plans expansion in US and Europe
Credihealth launches
medical loan facility
Credihealth, a medical assistance company,
has launched a medical loan facility on
its platform, partnering with banks, Non-
banking financial companies (NBFCs) and
fintech players like Rubique.
Users can now apply for medical loans via
Credihealth and make paperless in-principal
transactions to avail loans ranging from Rs
30,000 to Rs 50 lakh for a tenure starting from
six months to 48 months. The tie-up gives
it access to Rubique’s technology platform,
network of over 65 financial institution tie-
ups, and strong distribution across 29 cities.
Credihealth expects reaching out to a much
larger audience with its unique healthcare
proposition through the partnership and will
also benefit from fulfilment support enabled
through Rubique’s fulfilment centres.
For its future tie-ups as well, it is focused
on teaming up with only those financial
services players who are highly transparent
and give loans at attractive and fair rates. As
a one-stop-shop for medical loan sanctions,
Credihealth will forward the loan application
to all the banks and NBFCs for the necessary
approvals as part of this new service.
Sayre Therapeutics enter
into agreement with
Navidea Biopharma
Sayre Therapeutics with a portfolio of oncology
and immunology focused commercial products,
has entered into
an exclusive
license agreement
with Navidea
Biopharmaceuticals,
Inc, a company focused on the development and
commercialization of precision immunodiagnostic
agents and immunotherapeutic, for the development
and commercialization of ‘Tc 99m tilmanocept’ in
India.
The receptor-targeted, radiopharmaceutical
imaging agent was approved by the U.S. Food and
Drug Administration in 2013 and by the European
Medicines Agency in November 2014 under the
brand name LYMPHOSEEK.
‘Tc 99m Tilmanocept’ is already commercialized
in three major European Countries along with the
US and represents
Next-Generation
Standard of
Diagnosis for
Sentinel Lymph Node
Detection. Tc 99m Tilmanocept is approved for
guiding sentinel lymph node biopsy in patients with
clinically node negative breast cancer, squamous cell
carcinoma of the oral cavity, or melanoma.